361 related articles for article (PubMed ID: 32299680)
1. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E; Scully M; Ariceta G; Barbour T; Cataland S; Heyne N; Miyakawa Y; Ortiz S; Swenson E; Vallee M; Yoon SS; Kavanagh D; Haller H;
Kidney Int; 2020 Jun; 97(6):1287-1296. PubMed ID: 32299680
[TBL] [Abstract][Full Text] [Related]
2. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Ariceta G; Dixon BP; Kim SH; Kapur G; Mauch T; Ortiz S; Vallee M; Denker AE; Kang HG; Greenbaum LA;
Kidney Int; 2021 Jul; 100(1):225-237. PubMed ID: 33307104
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.
Gäckler A; Schönermarck U; Dobronravov V; La Manna G; Denker A; Liu P; Vinogradova M; Yoon SS; Praga M
BMC Nephrol; 2021 Jan; 22(1):5. PubMed ID: 33407224
[TBL] [Abstract][Full Text] [Related]
4. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.
Tanaka K; Adams B; Aris AM; Fujita N; Ogawa M; Ortiz S; Vallee M; Greenbaum LA
Pediatr Nephrol; 2021 Apr; 36(4):889-898. PubMed ID: 33048203
[TBL] [Abstract][Full Text] [Related]
5. Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome.
Syed YY
Drugs; 2021 Apr; 81(5):587-594. PubMed ID: 33738756
[TBL] [Abstract][Full Text] [Related]
6. Interventions for atypical haemolytic uraemic syndrome.
Pugh D; O'Sullivan ED; Duthie FA; Masson P; Kavanagh D
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012862. PubMed ID: 33783815
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
Barbour T; Scully M; Ariceta G; Cataland S; Garlo K; Heyne N; Luque Y; Menne J; Miyakawa Y; Yoon SS; Kavanagh D;
Kidney Int Rep; 2021 Jun; 6(6):1603-1613. PubMed ID: 34169200
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data.
Schönfelder K; Kühne L; Schulte-Kemna L; Kaufeld J; Rohn H; Kribben A; Schröppel B; Brinkkötter PT; Gäckler A
BMC Nephrol; 2024 Jun; 25(1):202. PubMed ID: 38898427
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Ariceta G
Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
[TBL] [Abstract][Full Text] [Related]
12. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
[TBL] [Abstract][Full Text] [Related]
13. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
[TBL] [Abstract][Full Text] [Related]
14. Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study.
Laber DA; Patel PC; Logothetis CN; Patel AK; Jaglal M; Haider M; Visweshwar N; Rajasekaran-Rathnakumar G; Eatrides J
Eur J Haematol; 2024 Mar; 112(3):450-457. PubMed ID: 37984551
[TBL] [Abstract][Full Text] [Related]
15. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.
Kourouklaris A; Ioannou K; Athanasiou I; Panagidou A; Demetriou K; Zavros M
J Med Case Rep; 2014 Sep; 8():307. PubMed ID: 25219386
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
[TBL] [Abstract][Full Text] [Related]
18. Complement Activation and Thrombotic Microangiopathies.
Palomo M; Blasco M; Molina P; Lozano M; Praga M; Torramade-Moix S; Martinez-Sanchez J; Cid J; Escolar G; Carreras E; Paules C; Crispi F; Quintana LF; Poch E; Rodas L; Goma E; Morelle J; Espinosa M; Morales E; Avila A; Cabello V; Ariceta G; Chocron S; Manrique J; Barros X; Martin N; Huerta A; Fraga-Rodriguez GM; Cao M; Martin M; Romera AM; Moreso F; Manonelles A; Gratacos E; Pereira A; Campistol JM; Diaz-Ricart M
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1719-1732. PubMed ID: 31694864
[TBL] [Abstract][Full Text] [Related]
19. Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan.
Ito S; Hataya H; Ashida A; Hamada R; Ishikawa T; Ishikawa Y; Shimono A; Konomoto T; Miyazawa T; Ogura M; Tanaka K; Kagami S
Nephrol Dial Transplant; 2023 Feb; 38(2):414-424. PubMed ID: 35438790
[TBL] [Abstract][Full Text] [Related]
20. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
